Charles Ryhee
Stock Analyst at TD Cowen
(2.46)
# 2,312
Out of 4,873 analysts
25
Total ratings
52.38%
Success rate
0.82%
Average return
Main Sectors:
Stocks Rated by Charles Ryhee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVS CVS Health | Maintains: Buy | $73 → $80 | $67.58 | +18.38% | 5 | Nov 25, 2024 | |
| WBA Walgreens Boots Alliance | Maintains: Buy | $16 → $14 | $11.35 | +23.35% | 6 | Oct 22, 2024 | |
| MCK McKesson | Maintains: Buy | $563 → $652 | $720.82 | -9.55% | 4 | May 8, 2024 | |
| CVX Chevron | Maintains: Outperform | $185 → $170 | $143.55 | +18.43% | 3 | Feb 24, 2023 | |
| EVH Evolent Health | Maintains: Outperform | $57 → $59 | $10.62 | +455.56% | 2 | Jan 30, 2023 | |
| CAH Cardinal Health | Maintains: Market Perform | $59 → $72 | $164.21 | -56.15% | 1 | Aug 16, 2022 | |
| OTRK Ontrak | Downgrades: Underperform | $3,150 → $810 | $1.05 | +77,042.86% | 2 | Aug 20, 2021 | |
| TDOC Teladoc Health | Maintains: Outperform | $240 → $188 | $8.00 | +2,250.00% | 1 | Aug 9, 2021 | |
| OSCR Oscar Health | Initiates: Market Perform | $29 | $20.02 | +44.86% | 1 | Mar 29, 2021 |
CVS Health
Nov 25, 2024
Maintains: Buy
Price Target: $73 → $80
Current: $67.58
Upside: +18.38%
Walgreens Boots Alliance
Oct 22, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $11.35
Upside: +23.35%
McKesson
May 8, 2024
Maintains: Buy
Price Target: $563 → $652
Current: $720.82
Upside: -9.55%
Chevron
Feb 24, 2023
Maintains: Outperform
Price Target: $185 → $170
Current: $143.55
Upside: +18.43%
Evolent Health
Jan 30, 2023
Maintains: Outperform
Price Target: $57 → $59
Current: $10.62
Upside: +455.56%
Cardinal Health
Aug 16, 2022
Maintains: Market Perform
Price Target: $59 → $72
Current: $164.21
Upside: -56.15%
Ontrak
Aug 20, 2021
Downgrades: Underperform
Price Target: $3,150 → $810
Current: $1.05
Upside: +77,042.86%
Teladoc Health
Aug 9, 2021
Maintains: Outperform
Price Target: $240 → $188
Current: $8.00
Upside: +2,250.00%
Oscar Health
Mar 29, 2021
Initiates: Market Perform
Price Target: $29
Current: $20.02
Upside: +44.86%